AVTX — Avalo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $404.72m
- $308.71m
- $0.06m
Annual cashflow statement for Avalo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -84.4 | -41.7 | -31.5 | -35.1 | -78.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 8.97 | 9.94 | 9.93 | -9.5 | 22.5 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.84 | 4.77 | -9.24 | -4.71 | 3.84 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -70.9 | -26.8 | -30.7 | -49.1 | -51.5 |
| Capital Expenditures | -0.113 | -0.095 | -0.158 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | 0.025 | 0.356 | -81.7 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.113 | -0.095 | -0.133 | 0.356 | -81.7 |
| Financing Cash Flow Items | 0 | — | — | — | -0.972 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 107 | -14.7 | 25 | 176 | 14.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 35.8 | -41.5 | -5.77 | 127 | -119 |